Back to discover
Drug

Acenocoumarol

In clinical development
ClassVitamin k epoxide reductase complex subunit 1 isoform 1 inhibitorEmerging researchLate-stage development
Also known as 3-(alpha-(4'-Nitrophenyl)-beta-acetylethyl)-4-hydroxycoumarin, 3-(alpha-(p-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin, 3-(alpha-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin, 3-(alpha-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin+13 more

3-(alpha-(4'-Nitrophenyl)-beta-acetylethyl)-4-hydroxycoumarin, 3-(alpha-(p-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin, 3-(alpha-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin, 3-(alpha-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin, 3-(alpha-p-Nitrophenyl-beta-acetylethyl)-4-hydroxycoumarin, 4-Hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-2H-1-benzopyran-2-one, Acenokumarin, Nicoumalone, Nicumalon, Nitrophenylacetylethyl-4-hydroxycoumarine, Nitrovarfarian, Nitrowarfarin, Acenocoumarin, Acenocumarol, Acenocumarolo, Acénocoumarol, Acenocoumarolum.

RxNorm154ChEMBLCHEMBL397420ATCB01AA07UNIII6WP63U32H
1
Research papers
VKORC1
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Rivaroxaban Plus Aspirin Versus Acenocoumarol to Manage Recurrent Venous Thromboembolic Events Despite Systemic Anticoagulation With Rivaroxaban

Clinical trial2022-07-01Completed · ClinicalTrials.gov

Start or STop Anticoagulants Randomised Trial (SoSTART) After Spontaneous Intracranial Haemorrhage

Clinical trial2021-03-26Completed · ClinicalTrials.gov

Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography

Clinical trial2018-07-01Primary completion · ClinicalTrials.gov

Rivaroxaban Versus Acenocumarol for Secondary Thromboprophylaxis in Patients With Antiphospholipid Syndrome: a Randomized, Prospective, Phase III Study. Analysis of Stratification Prognostic Factors

Clinical trial2017-12-31Completed · ClinicalTrials.gov

A PHASE I, OPEN-LABEL, MULTICENTER, 3-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF ACENOCOUMAROL IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY

Clinical trial2014-06-01Completed · ClinicalTrials.gov

Long Term Subcutaneous Tinzaparin Compared With Tinzaparin and Oral Anticoagulants in the Treatment of the Acute Pulmonary Embolism

Clinical trial2009-02-01Completed · ClinicalTrials.gov

Safety Study of Vitamin K2 During Anticoagulation in Human Volunteers

Clinical trial2007-12-01Completed · ClinicalTrials.gov

Phase IV, Randomized, Open-Label Trial Comparing Long-Term Subcutaneous Low-Molecular Weight Heparin With Oral Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis

Clinical trial2005-01-01Completed · ClinicalTrials.gov

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

Research2003-07-01The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Acenocoumarol
Aliases & brands
3-(alpha-(4'-Nitrophenyl)-beta-acetylethyl)-4-hydroxycoumarin3-(alpha-(p-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin3-(alpha-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin3-(alpha-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin3-(alpha-p-Nitrophenyl-beta-acetylethyl)-4-hydroxycoumarin4-Hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-2H-1-benzopyran-2-oneAcenokumarinNicoumaloneNicumalonNitrophenylacetylethyl-4-hydroxycoumarineNitrovarfarianNitrowarfarinAcenocoumarinAcenocumarolAcenocumaroloAcénocoumarolAcenocoumarolum
RxNorm CUI
154
ChEMBL ID
CHEMBL397420
ATC codes
B01AA07
UNII
I6WP63U32H
Primary mechanism
Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Vitamin K epoxide reductase complex subunit 1
VKORC1 · Q9BQB6
INHIBITORVitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor

Clinical trials

8 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
8
registered trials across all phases
LATEST COMPLETION 2022
7
Late-stage (III+)
7
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 8
Phase 11Phase 2 / 31Phase 32Phase 43Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography

Unknown statusPH IVSemmelweis University Heart and Vascular Centern=2002019

Long Term Subcutaneous Tinzaparin Compared With Tinzaparin and Oral Anticoagulants in the Treatment of the Acute Pulmonary Embolism

CompletedPH IVComplejo Hospitalario Xeral-Calden=1022009

Phase IV, Randomized, Open-Label Trial Comparing Long-Term Subcutaneous Low-Molecular Weight Heparin With Oral Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis

CompletedPH IVHospital Universitari de Bellvitgen=2412005

Rivaroxaban Plus Aspirin Versus Acenocoumarol to Manage Recurrent Venous Thromboembolic Events Despite Systemic Anticoagulation With Rivaroxaban

CompletedPH II/IIIInstituto Mexicano del Seguro Socialn=582022

Start or STop Anticoagulants Randomised Trial (SoSTART) After Spontaneous Intracranial Haemorrhage

CompletedPH IIIUniversity of Edinburghn=2032021

Recent completions

Trials that read out recently, adding to the completed evidence base.

Rivaroxaban Plus Aspirin Versus Acenocoumarol to Manage Recurrent Venous Thromboembolic Events Despite Systemic Anticoagulation With Rivaroxaban

CompletedPH II/IIIInstituto Mexicano del Seguro Socialn=582022

Start or STop Anticoagulants Randomised Trial (SoSTART) After Spontaneous Intracranial Haemorrhage

CompletedPH IIIUniversity of Edinburghn=2032021

Rivaroxaban Versus Acenocumarol for Secondary Thromboprophylaxis in Patients With Antiphospholipid Syndrome: a Randomized, Prospective, Phase III Study. Analysis of Stratification Prognostic Factors

CompletedPH IIIHospital Universitari Vall d'Hebron Research Instituten=1902017

A PHASE I, OPEN-LABEL, MULTICENTER, 3-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF ACENOCOUMAROL IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY

CompletedPH IHoffmann-La Rochen=92014

Long Term Subcutaneous Tinzaparin Compared With Tinzaparin and Oral Anticoagulants in the Treatment of the Acute Pulmonary Embolism

CompletedPH IVComplejo Hospitalario Xeral-Calden=1022009

Safety Study of Vitamin K2 During Anticoagulation in Human Volunteers

CompletedN/AMaastricht Universityn=202007

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Journals, researchers & institutions
Top journals
  • The New England journal of medicine1
Leading researchers
  • Baker RI1
  • Bowden C1
  • Gent M1
  • Haley S1
  • Julian JA1
  • Kakkar AK1
  • Kovacs MJ1
  • Lee AY1
Leading institutions
free-text, unnormalised
  • McMaster University1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Dalteparin

Studied across 5 of the same disease areas as Acenocoumarol in the shared literature.

5 shared diseases1 shared paper
Warfarin

Studied across 5 of the same disease areas as Acenocoumarol in the shared literature.

5 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials